Tiffany Ossi MD (She/Her)
Preventive Medicine, Obesity Medicine & Nutrition
Resident Physician
Join to View Full Profile
506 6th StBrooklyn, NY 11215
Phone+1 718-780-3000
Fax+1 718-780-3259
Dr. Ossi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York-Presbyterian Brooklyn Methodist HospitalResidency, Internal Medicine, 2022 - 2025
University of Florida College of MedicinePostdoctoral Clinical Fellowship, Cardiovascular Disease, 2021 - 2022
St. George's University School of MedicineClass of 2021
Cleveland Clinic FloridaSub-Internship Internal Medicine, 2020 - 2020
University of Miami Leonard M. Miller School of MedicineSub-Internship Internal Medicine, 2019 - 2019
University of FloridaBS, Chemistry, 2012 - 2017
Certifications & Licensure
CA State Medical License 2024 - 2027
POCUS AcademyCardiac POCUS- POCUS AcademyFundamentals of POCUS
Awards, Honors, & Recognition
- Founders Scholarship Recipient St. George’s University School of Medicine, 2017
Clinical Trials
- Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus Start of enrollment: 2019 Aug 22
- Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus Start of enrollment: 2021 Mar 31
- Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Start of enrollment: 2019 Sep 06
Publications & Presentations
PubMed
- 1 citationsClopidogrel-Mediated P2YInhibition According to Renal Function in Patients With Diabetes Mellitus and CAD.Luis Ortega-Paz, Francesco Franchi, Fabiana Rollini, Mattia Galli, Latonya Been
JACC. Basic to Translational Science. 2024-07-01 - 6 citationsSwitching from Dual Antiplatelet Therapy with Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition with Aspirin Plus Vascular-Dose Rivaroxaban: The Switching Anti...Luis Ortega-Paz, Francesco Franchi, Fabiana Rollini, Mattia Galli, Latonya Been
Thrombosis and Haemostasis. 2024-03-01 - 13 citationsCangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study.Francesco Franchi, Luis Ortega-Paz, Fabiana Rollini, Mattia Galli, Latonya Been
JACC. Cardiovascular Interventions. 2023-01-09
Journal Articles
- Switching From Dual Antiplatelet Treatment Regimens With Aspirin Plus a P2Y12 Inhibitor to Dual Pathway Inhibition With Low-Dose Rivaroxaban in Adjunct to Aspirin in P...Luis G Ortega-Paz, Fabiana Rollini, Mattia Galli, Latonya Been, Ghussan Ghanem, Awss Shalhoub, Tiffany Ossi, Andrea Rivas, Xuan Zhou, Andres Pineda, Siva Suryadevara, ..., Circulation, 10/30/2022
Professional Memberships
- Member
- Member
- American Society of Preventive Cardiology - ASPCMember
- Cardiometabolic Health CongressMember
- American Society of Lifestyle MedicineMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
